The emerging recognition that chronic obstructive pulmonary disease (COPD) is a complex disorder, characterized not only by local pulmonary inflammation, but also by systemic inflammation that might have an adverse impact on various extrapulmonary organs, such as the blood vessels and the heart, among others, emphasizes the need for new and more effective forms of therapy for this debilitating disorder. Fortunately, many of the 'standard' therapeutic options used to treat COPD have the potential to influence systemic inflammation. Moreover, several new therapeutic strategies aimed at controlling the underlying inflammatory processes of COPD more specifically are under development. Unfortunately, we still do not know whether treatment of lung inflammation decreases, for example, the risk of acute cardiac events, progression of atherosclerosis or thrombotic events. It is also unclear whether, alternatively, treatment of heart disease can affect the progression of lung disease. Nonetheless, initial data seem to indicate that drugs, such as statins, ACE inhibitors, AT1 receptor blockers and PPAR agonists, used to treat a co-morbid condition have the potential to benefit COPD patients. © 2007 Elsevier Ltd. All rights reserved.

Cazzola, M., Matera, M.G., Rogliani, P., & Page, C. (2007). Treating systemic effects of COPD. TRENDS IN PHARMACOLOGICAL SCIENCES, 28(10), 544-550 [10.1016/j.tips.2007.09.006].

Treating systemic effects of COPD

CAZZOLA, MARIO;ROGLIANI, PAOLA;
2007

Abstract

The emerging recognition that chronic obstructive pulmonary disease (COPD) is a complex disorder, characterized not only by local pulmonary inflammation, but also by systemic inflammation that might have an adverse impact on various extrapulmonary organs, such as the blood vessels and the heart, among others, emphasizes the need for new and more effective forms of therapy for this debilitating disorder. Fortunately, many of the 'standard' therapeutic options used to treat COPD have the potential to influence systemic inflammation. Moreover, several new therapeutic strategies aimed at controlling the underlying inflammatory processes of COPD more specifically are under development. Unfortunately, we still do not know whether treatment of lung inflammation decreases, for example, the risk of acute cardiac events, progression of atherosclerosis or thrombotic events. It is also unclear whether, alternatively, treatment of heart disease can affect the progression of lung disease. Nonetheless, initial data seem to indicate that drugs, such as statins, ACE inhibitors, AT1 receptor blockers and PPAR agonists, used to treat a co-morbid condition have the potential to benefit COPD patients. © 2007 Elsevier Ltd. All rights reserved.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/10 - Malattie dell'Apparato Respiratorio
eng
Con Impact Factor ISI
4 (4 fluorophenyl) 2 (4 methylsulfinylphenyl) 5 (4 pyridyl)imidazole; 4 [4 (4 fluorophenyl) 1 (3 phenylpropyl) 5 (4 pyridinyl) 1h imidazol 2 yl] 3 butyn 1 ol; 4 [4 (4 fluorophenyl) 5 (2 methoxy 4 pyrimidinyl) 1 imidazolyl]cyclohexanol; acetylcysteine; angiotensin 2 receptor antagonist; antioxidant; beta 2 adrenergic receptor stimulating agent; bronchodilating agent; corticosteroid; dipeptidyl carboxypeptidase inhibitor; doramapimod; enoxaparin; etanercept; glutathione derivative; glycosaminoglycan; heparin; hydroxymethylglutaryl coenzyme A reductase inhibitor; infliximab; irbesartan; mevinolin; muscarinic receptor blocking agent; phosphodiesterase IV inhibitor; pioglitazone; rosiglitazone; selenium derivative; simvastatin; superoxide dismutase; theophylline; antiinflammatory activity; atherosclerosis; cardiovascular risk; chronic obstructive lung disease; combination chemotherapy; comorbidity; corticosteroid therapy; disease control; drug activity; drug efficacy; drug fatality; gastrointestinal symptom; heart arrhythmia; heart disease; human; low drug dose; muscle atrophy; nonhuman; oxygen therapy; pneumonia; priority journal; pulmonary rehabilitation; review; smoking cessation; systemic disease; thrombosis; Adrenal Cortex Hormones; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Bronchodilator Agents; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Phosphodiesterase Inhibitors; PPAR gamma; Pulmonary Disease, Chronic Obstructive; Smoking Cessation
Cazzola, M., Matera, M.G., Rogliani, P., & Page, C. (2007). Treating systemic effects of COPD. TRENDS IN PHARMACOLOGICAL SCIENCES, 28(10), 544-550 [10.1016/j.tips.2007.09.006].
Cazzola, M; Matera, M; Rogliani, P; Page, C
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
trends.pdf

accesso aperto

Descrizione: articolo pdf
Dimensione 399.04 kB
Formato Adobe PDF
399.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/42211
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 22
social impact